beta-Epoetin

Epoetin beta (rhEPO) is a recombinant form of erythropoietin. Epoetin beta is responsible for the maintenance of erythropoiesis and can be used for anaemia research[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

Epoetin beta (rhEPO) (1000 IU/kg; s.c.; three times per week over 14 days) prevents anaemia and enhances the radiosensitivity of solid growing DS-sarcomas[2]. Animal Model: Male Sprague-Dawley rats, body weight 140-170 g[2] Dosage: 1000 IU/kg Administration: Subcutaneous injection, three times per week over 14 days starting 9 days before tumour implantation. Solid DS-sarcomas were induced by injecting DS-sarcoma cells (0.4 mL, approximately 104 cells/uL) subcutaneously into the hind food dorsum. A prolonged anaemia was induced in all animals by a single i.v. dose of carboplatin (45 mg/kg dissolved in isotonic saline at a concentration of 20 mg/mL) into the tail vein 3 days before tumour implantation. Result: Prevented anaemia and significantly increased the radiosensitivity of solid growing DS-sarcomas, tumours showing pronounced hypoxia even under non-anaemic control conditions.

[1]. Cheer SM, et al. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs. 2004;64(3):323-46.

[2]. Thews O, et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer. 1998 Sep;78(6):752-6.